RT Journal Article
T1 Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts
A1 Calleja-Panero, José Luis
A1 Andrade, Raúl J.
A1 Bañares, Rafael
A1 Crespo, Javier
A1 Esteban, Rafael
A1 Jarque, Isidro
A1 Mingot-Castellano, María Eva
A1 Romero-Gómez, Manuel
A1 Muñoz-Peñín, Rocío
A1 Bentley, Roy
A1 Shepherd, John
A1 Gil, Alicia
K1 Thrombocytopenia
K1 Chronic liver disease
K1 Platelet transfusion
K1 Delphi
K1 Epidemiology
K1 Treatment
K1 Thrombopoietin receptor agonists
K1 Trombocitopenia
K1 Transfusión de plaquetas
K1 Técnica Delfos
K1 Epidemiología
K1 Terapéutica
AB Background: chronic liver disease (CLD) patients often present thrombocytopenia (TCP) and when severe, it may prevent them from undergoing necessary invasive procedures due to an increased bleeding risk. The lack of scientific evidence makes it impossible to determine key aspects of the current management and associated healthcare burden of these patients in Spain.Purpose: to gain insight into the current situation of patients with CLD-associated severe TCP undergoing invasive procedures in Spain, based on the experience of clinical experts.Methods: national Delphi study involving 32 medical experts.Results: the estimated prevalence of CLD-associated severe TCP is approximately 5,967, with an annual incidence of 1,148 new patients. Patients undergo a median of 1 (0-3) invasive procedures/year. Platelet transfusions (PTs) are the standard option to raise platelet counts and are associated with significant burden. The achievement of target platelet levels (≥ 50 x 109/l) after a transfusion is not routinely measured. The lack of effectiveness and short life span of transfused platelets can lead to procedure cancellations and bleeding events, which potentially affect patient outcomes. Adverse events occur in 1-25 % of patients, including mild (febrile and allergic reactions) and severe events (e.g., transfusion-related acute lung injury). Between 5-15 % of patients are unfit to receive PTs and approximately 3 % are treated off-label with thrombopoietin receptor agonists.Conclusions: this study provides a snapshot of the current situation in Spain, highlighting that the current management is poorly standardized and suboptimal in some cases. The results suggest the benefit of developing a consensus document to address some of these shortcomings and to advance in the search for alternatives to PTs.
PB SEPD y Arán Ediciones, S.L.
SN 1130-0108
YR 2020
FD 2020
LK http://hdl.handle.net/10668/3490
UL http://hdl.handle.net/10668/3490
LA en
NO Calleja-Panero JL, Andrade RJ, Bañares R, Crespo J, Esteban R, Jarque I, et al. Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. Rev Esp Enferm Dig. 2020;112(10):778-783.
DS RISalud
RD Apr 9, 2025